<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03028103</url>
  </required_header>
  <id_info>
    <org_study_id>EZH-105</org_study_id>
    <nct_id>NCT03028103</nct_id>
  </id_info>
  <brief_title>Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients</brief_title>
  <official_title>An Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize the Effects of a Moderate CYP3A Inhibitor on the Pharmacokinetics of Tazemetostat (EPZ-6438) (Part A), the Effects of Tazemetostat on the Pharmacokinetics of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on the Pharmacokinetics of Tazemetostat (Part B) in Subjects With B-cell Lymphoma or Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epizyme, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Epizyme, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label, two-part, safety, PK, and activity study designed to
      characterize the DDI potential of tazemetostat. Tazemetostat will be taken orally BID
      continuously in 28-day cycles in both study parts.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 27, 2017</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Effect of CYP3A inhibition by fluconazole on the PK of tazemetostat (AUC0-t, AUC0-8)</measure>
    <time_frame>Days 15 and 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: Cmax of tazemetostat during co-administration with fluconazole</measure>
    <time_frame>Days 15 and 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: The potential of tazemetostat to inhibit or induce CYP2C8 using repaglinide as a probe substrate (AUC0-t, AUC0-∞)</measure>
    <time_frame>Days 1 and 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Cmax of repaglinide during co-administration with tazemetostat</measure>
    <time_frame>Days 1 and 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: The potential of tazemetostat to inhibit or induce CYP2C19 using omeprazole as probe a substrate (AUC0-t, AUC0-∞)</measure>
    <time_frame>Days 1 and 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Cmax of omeprazole during co-administration with tazemetostat</measure>
    <time_frame>Days 1 and 16</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Effect of increased gastric pH by omeprazole on the PK of tazemetostat (AUC0-t, AUC0-8)</measure>
    <time_frame>Days 16 and 19</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Cmax of tazemetostat during co-administration with omeprazole</measure>
    <time_frame>Days 16 and 19</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment-emergent adverse events as a measure of safety</measure>
    <time_frame>Part A: Day 15 predose and through 8 hours post dose. Day 19 predose and through 8 hours post dose Part B: Day 1 through 16 and Day 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: PK of tazemetostat and its metabolites after administration alone and with fluconazole (AUC0-t, AUC0-8)</measure>
    <time_frame>Days 15 and 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Tmax of tazemetostat after administration alone with fluconazole</measure>
    <time_frame>Days 15 and 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: t1/2 of tazemetostat after administration alone with fluconazole</measure>
    <time_frame>Days 15 and 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Cmax of tazemetostat metabolites after administration alone and with fluconazole</measure>
    <time_frame>Days 15 and 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Tmax of tazemetostat metabolites after administration alone and with fluconazole</measure>
    <time_frame>Days 15 and 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: t1/2 of tazemetostat metabolites after administration alone and with fluconazole</measure>
    <time_frame>Days 15 and 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Exposure of fluconazole after administration of 400 mg once daily for 4 days (AUC0-8)</measure>
    <time_frame>Day 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Cmax of fluconazole after administration of 400mg once daily for 4 days</measure>
    <time_frame>Day 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: Tmax of fluconazole after administration of 400mg once daily for 4 days</measure>
    <time_frame>Day 19</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part A: The antitumor activity of Tazemetostat will be assessed in patients with diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL), follicular lymphoma (FL) or advanced solid tumors .</measure>
    <time_frame>Within 28 days of Day 1, 8 weeks, 16 weeks, 24 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: The antitumor activity of Tazemetostat will be assessed in patients with diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL), follicular lymphoma (FL) or advanced solid tumors..</measure>
    <time_frame>Within 28 days of Day 1, 8 weeks, 16 weeks, 24 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <condition>Primary Mediastinal Lymphoma</condition>
  <condition>Mantle Cell Lymphoma</condition>
  <condition>Advanced Solid Tumor</condition>
  <condition>Marginal Zone Lymphoma</condition>
  <arm_group>
    <arm_group_label>Part A and B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part A: Subjects enrolled in Part A will receive treatment with oral tazemetostat tablets 400 mg BID for 24 days beginning on Day 1. Subjects will receive fluconazole 400 mg once daily for 4 days starting on Day 16. Tazemetostat 400 mg BID will continue through Day 24. Subjects will then receive tazemetostat 800 mg BID starting on Day 25.
Part B: Subjects enrolled in Part B will receive single oral doses of repaglinide 0.25 mg and omeprazole 20 mg on Day 1. Administration of tazemetostat 800 mg BID will begin on Day 2. On Day 16, subjects again will receive single oral doses of repaglinide 0.25 mg and omeprazole 20 mg approximately 1 hour after the morning dose of tazemetostat. Subjects also will receive omeprazole 20 mg once daily in the morning on Days 16 through 19.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazemetostat</intervention_name>
    <description>Tazemetostat is a selective oral small molecule inhibitor of EZH2</description>
    <arm_group_label>Part A and B</arm_group_label>
    <other_name>EPZ-6438, E7438</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
    <description>200mg will be orally administered QD for 4 days in order to determine CYP3A4 inhibition when administered concomitantly with tazemetostat</description>
    <arm_group_label>Part A and B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>Using omeprazole as a probe substrate, 20mg will be orally administered for a total of 5 days in order to determine the potential of tazemetostat to inhibit or induce CYP2C19. Omeprazole is also being used to determine the effect of increased gastric pH on metabolism of tazemetostat.</description>
    <arm_group_label>Part A and B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Repaglinide</intervention_name>
    <description>Using repaglinide as a probe substrate, 25mg will be orally administered for a total of 2 days in order to determine the potential of tazemetostat to inhibit or induce CYP2C8.</description>
    <arm_group_label>Part A and B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Male or female ≥ 18 years of age at time of consent

          2. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

          3. Has histologically confirmed diffuse large B-cell lymphoma (DLBCL), primary
             mediastinal B-cell lymphoma (PMBCL), marginal zone lymphoma (MZL), mantle cell
             lymphoma (MCL) or histologically and/or cytologically confirmed advanced or metastatic
             solid tumor and have relapsed or refractory disease following at least two lines of
             prior standard therapy, including alkylator/anthracycline (unless anthracycline-based
             chemotherapy is contraindicated)/anti-CD20-based therapy (R-CHOP; rituximab,
             doxorubicin, cyclophosphamide, vincristine, and prednisolone or prednisone, or
             equivalent) AND must be considered unable to benefit from intensification treatment
             with autologous hematopoietic stem cell transplantation (ASCT), as defined by meeting
             at least one of the following criteria:

               1. Relapsed following, or refractory to, previous ASCT

               2. Did not achieve at least a partial response (PR) to a standard salvage regimen
                  (e.g., R-ICE; rituximab, ifosfamide, carboplatin, etoposide, or R-DHAP;
                  rituximab, dexamethasone, cytarabine, cisplatin)

               3. Ineligible for intensification treatment due to age or significant comorbidity

               4. Ineligible for intensification treatment due to failure to mobilize an acceptable
                  number of hematopoietic stem cells

               5. Refused intensification treatment and/or ASCT

          4. Transformed disease is permitted

          5. Must have evaluable or measurable disease

          6. Has all prior treatment (i.e., chemotherapy, immunotherapy, radiotherapy) related
             clinically significant toxicities resolve to ≤ Grade 1 per NCI CTCAE, Version 4.03 or
             are clinically stable and not clinically significant, at time of consent

          7. Time required between the last dose of the latest therapy and the first dose of study
             drug:

               1. Chemotherapy: cytotoxic At least 21 days

               2. Chemotherapy: nitrosoureas At least 6 weeks

               3. Chemotherapy: non-cytotoxic (e.g., small molecule inhibitor) At least 14 days

               4. Monoclonal antibody (ies) At least 28 days

               5. Non-antibody immunotherapy (e.g., tumor vaccine) At least 42 days

               6. At least 14 days for stereotactic radiosurgery

               7. At least 12 weeks for craniospinal, ≥50% radiation of pelvis, or total body
                  irradiation prior to first dose of study drug

               8. Autologous hematopoietic cell infusion after high dose therapy At least 60 days

               9. Hematopoietic growth factor At least 14 days

          8. Has adequate hematologic (bone marrow [BM] and coagulation factors), renal and hepatic
             function

               1. Hemoglobin ≥9 g/dL

               2. Platelets ≥75,000/mm3 (≥75 × 10^9/L)

               3. ANC: for patients with lymphoma ≥750/mm3 (≥0.75 × 10^9/L), for patients with
                  advanced solid tumors ≥1,000/mm3 (≥1.0 × 10^9/L),

               4. PT &lt;1.5 ULN

               5. PTT &lt;1.5 ULN

               6. eGFR ≥ 50 mL/min/1.73 m2

               7. Conjugated bilirubin &lt;1.5 × ULN

               8. AST &lt;3 × ULN

               9. ALT &lt;3 × ULN

             NOTE: Laboratory results obtained during screening should be used to determine
             eligibility criteria. In situations where laboratory results are outside the permitted
             range, the investigator may retest the subject and the subsequent within range
             screening result may be used to determine the subject's eligibility.

          9. Has a QT interval corrected by Fridericia's formula (QTcF) ≤480 msec

         10. Subjects with a history of Hepatitis B or C are eligible on the condition that
             subjects have adequate liver function as defined by the protocol and are hepatitis B
             surface antigen negative and/or have undetectable HCV RNA.

         11. Male subjects must refrain from donating sperm starting at the planned first dose of
             investigational product (IP) until 30 days following the last dose of IP

         12. Male subjects with a female partner of childbearing potential must:

               1. Be vasectomized, or

               2. Remain abstinent or use a condom as defined in Section 8.3.8.4.2, starting at the
                  planned first dose of IP until 30 days following the last dose of IP. The
                  reliability of sexual abstinence should be evaluated in relation to the duration
                  of the clinical trial and the preferred and usual lifestyle of the subject.
                  Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, or post-ovulation
                  methods) and withdrawal are not acceptable methods of contraception.

         13. Female partners of male subjects who are of childbearing potential must also adhere to
             one of the following:

               1. Placement of an intrauterine device or intrauterine system.

               2. Established use of oral, injected, or implanted hormonal methods of contraception
                  or use of a barrier method of contraception.

               3. Progesterone only oral contraception, where inhibition of ovulation is not the
                  primary mode of action.

         14. Women of childbearing potential or female partners of male subjects must abide by the
             contraception measures defined by the protocol

        Exclusion criteria:

          1. Is pregnant or nursing

          2. Has active central nervous system (CNS) or leptomeningeal metastasis

          3. Has had a prior malignancy other than the malignancies under study Exception: Subject
             who has been disease-free for 3 years, or a subject with a history of a completely
             resected non-melanoma skin cancer or successfully treated in situ carcinoma are
             eligible.

          4. Has had major surgery within 3 weeks prior to enrollment NOTE: Minor surgery (e.g.,
             minor biopsy, central venous catheter placement) is permitted within 3 weeks prior to
             enrollment.

          5. Is unwilling to exclude grapefruit juice, Seville oranges, and grapefruit from the
             diet and all foods that contain those fruits from time of enrollment to while on study

          6. Has cardiovascular impairment, history of congestive heart failure greater than NYHA
             Class II uncontrolled arterial hypertension, unstable angina, myocardial infarction,
             or stroke within 6 months prior to the planned first dose of tazemetostat; or
             ventricular cardiac arrhythmia requiring medical treatment

          7. Subjects taking medications that are known potent or moderate inducers/ inhibitors of
             CYP3A4 (including St. John's Wort)

          8. Has an active infection or recent history (&lt;30 days before study drug administration)
             requiring systemic treatment

          9. Is immunocompromised, including subjects with known human immunodeficiency virus (HIV)
             infection

         10. Has known hypersensitivity to any of the components of IP.

         11. Is unable to take oral medications, has a history of surgery that would interfere with
             the administration or absorption of oral medication, has malabsorption syndrome or any
             other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea or vomiting)
             that might impair the bioavailability of IP

         12. Has an uncontrolled intercurrent illness including, but not limited to, uncontrolled
             infection, or psychiatric illness/social situations that would limit compliance with
             study requirements.

         13. Is unwilling to adhere to contraception criteria from time of enrollment in study to
             at least 30 days after last dose of IP.

         14. A history of bleeding (i.e., hemoptysis, hematuria, gastrointestinal blood loss,
             epistaxis, or others with greater than Grade 1 according to NCI CTCAE Version 4.03)
             within 1 month prior to beginning therapy or any clinical indications of current
             active bleeding.

         15. Clinical history, current alcohol (ethanol), or illicit drug use which, in the
             judgment of the investigator, will interfere with the subject's ability to comply with
             the dosing schedule and protocol-specified evaluations.

         16. Regular alcohol consumption averaging more than seven drinks/week for women and 14
             drinks/week for men within 6 months of screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Arizona Cancer Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85719</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 19, 2016</study_first_submitted>
  <study_first_submitted_qc>January 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2017</study_first_posted>
  <last_update_submitted>May 18, 2018</last_update_submitted>
  <last_update_submitted_qc>May 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
    <mesh_term>Lymphoma, B-Cell, Marginal Zone</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Repaglinide</mesh_term>
    <mesh_term>Cytochrome P-450 CYP3A Inhibitors</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

